← Back to Clinical Trials
Recruiting NCT06561165

NCT06561165 Multifocal HD-tDCS and Motor Function

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06561165
Status Recruiting
Phase
Sponsor University of Michigan
Condition Healthy
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-02-25
Primary Completion 2027-01-25

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Standard HD-tDCS interventionMultifocal network targeted HD-tDCS interventionFunctional Magnetic Resonance Imaging (fMRI)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-02-25 with a primary completion date of 2027-01-25.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to understand how the brain controls movement and how Non-invasive Brain Stimulation (NIBS) with a technique called High-density transcranial direct current stimulation (HD-tDCS) can alter brain processes to improve behavior. Participants in this study will be randomized to either HD-tDCS with standard intervention or personalized dose-controlled multifocal network-targeted HD-tDCS. The hypothesis is that dexterous hand function will improve after a standard HD-tDCS dose and increase even more after personalized dose-controlled multifocal network-targeted HD-tDCS.

Eligibility Criteria

Inclusion Criteria: * Participants should be in good health with normal or corrected-to-normal visual acuity * Right handed * No history of neurological disorder * English speaker * Able to provide written consent prior to admission Exclusion Criteria: * Left-handed * Participants are pregnant, suspect pregnancy or are attempting to become pregnant * Have a pacemaker, intracardiac lines or any other medically implanted device or medicine pump * Have cochlear hearing implants * Taking drugs known to influence neural receptors that facilitate neuroplasticity (see protocol) * Have non removable body piercings or have foreign objects in body * Have metal anywhere in the head that could increase risk of serious injury (not including braces, dental fillings, etc.) (see protocol) * Have a personal or family history of seizure/epilepsy * Taking prescription drugs that lower the threshold for seizures * Recent history of excessive alcohol consumption * History of alcohol addiction/dependence * Recent history of recreational drug use * History of drug addiction/dependence * Recent history of recreational drug use * History of drug addiction/dependence * Diagnosed with a stroke, brain hemorrhage, brain tumor, encephalitis. * Diagnosed with multiple sclerosis * Diagnosed with Parkinson's disease or Alzheimer's disease * Diagnosed with depression in the past 6 months * Diagnosed with attention deficit disorder, schizophrenia, manic depressive (bipolar) disorder * Diagnosed with normal pressure hydrocephalus or increased intra-cranial pressure * Diabetes requiring insulin treatment * Any serious heart disorder or liver disease

Contact & Investigator

Central Contact

Michael Vesia, PhD

✉ mvesia@umich.edu

📞 734-764-5237

Principal Investigator

Michael Vesia, PhD

PRINCIPAL INVESTIGATOR

University of Michigan

Frequently Asked Questions

Who can join the NCT06561165 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, up to 85 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06561165 currently recruiting?

Yes, NCT06561165 is actively recruiting participants. Contact the research team at mvesia@umich.edu for enrollment information.

Where is the NCT06561165 trial being conducted?

This trial is being conducted at Ann Arbor, United States.

Who is sponsoring the NCT06561165 clinical trial?

NCT06561165 is sponsored by University of Michigan. The principal investigator is Michael Vesia, PhD at University of Michigan. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology